➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Dow
AstraZeneca
Boehringer Ingelheim
Moodys
Baxter

Last Updated: August 14, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TIGECYCLINE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Tigecycline

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00079885 Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2003-11-01 To compare the efficacy and safety of tigecycline with those of levofloxacin in the treatment of subjects with CAP requiring hospitalization. The co-primary efficacy endpoints in the study will be the clinical response in the clinically evaluable population and the clinical response in the clinical modified intent-to-treat population at the TOC visit. The primary efficacy analyses will first determine whether tigecycline is noninferior to levofloxacin. If tigecycline is found to be noninferior, the analyses will determine whether tigecycline is statistically better than levofloxacin.
NCT00079976 Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA) Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2003-10-01 To evaluate the safety and efficacy of tigecycline in the treatment of selected serious infections caused by VRE. The primary efficacy endpoint will be the clinical response for all subjects.
NCT00079989 Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative Organisms Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2003-12-01 To evaluate the safety and efficacy of tigecycline in the treatment of subjects with selected serious infections caused by resistant gram-negative bacteria, eg, Acinetobacter baumannii, Enterobacter species, Klebsiella pneumoniae or other resistant gram-negative pathogens, for whom antibiotics have failed or who cannot tolerate other appropriate antimicrobial therapies. The primary efficacy endpoint will be the clinical response.
NCT00080496 Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2003-07-01 To compare the efficacy and safety of the tigecycline regimen with that of the imipenem/cilastatin regimen in subjects with nosocomial pneumonia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tigecycline

Condition Name

Condition Name for Tigecycline
Intervention Trials
Cross Infection 4
Skin Diseases, Infectious 3
Bacterial Pneumonia 3
Intra-Abdominal Infection 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Tigecycline
Intervention Trials
Infection 30
Communicable Diseases 24
Intraabdominal Infections 14
Pneumonia 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Tigecycline

Trials by Country

Trials by Country for Tigecycline
Location Trials
United States 116
China 28
Canada 16
Argentina 13
Korea, Republic of 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Tigecycline
Location Trials
California 9
Florida 7
Ohio 7
Pennsylvania 6
Georgia 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Tigecycline

Clinical Trial Phase

Clinical Trial Phase for Tigecycline
Clinical Trial Phase Trials
Phase 4 13
Phase 3 18
Phase 2/Phase 3 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Tigecycline
Clinical Trial Phase Trials
Completed 32
Not yet recruiting 5
Recruiting 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Tigecycline

Sponsor Name

Sponsor Name for Tigecycline
Sponsor Trials
Wyeth is now a wholly owned subsidiary of Pfizer 23
Pfizer 10
Department of Health and Human Services 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Tigecycline
Sponsor Trials
Other 42
Industry 38
U.S. Fed 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Harvard Business School
Dow
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.